Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Treprostinil in PH-COPD
NCT03012646Phase 2Withdrawn
- Sponsor
- United Therapeutics Corporation
- Start
- Apr 2017
- Primary completion
- Apr 2019
- Modality
- Orthosteric Ligands
01
Overview
A Phase 2 trial of treprostinil in pulmonary hypertension (PH), sponsored by United Therapeutics Corporation. Planned start Apr 2017; status: withdrawn.
02
Drugs
treprostinil
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT03012646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03012646.